|
|
|
|
|
ADELAIDE, AUS, Apr 2, 2020 - (ACN Newswire) - Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has appointed US-based Dr Caroline Popper, MBBS, MPH as Board Chair as part of its APAC clinical trials bioanalytics growth plans.
 | | Dr Caroline Popper |
More than 38% of Agilex Biolabs' biotech clients already come from the APAC region - primarily from China and South Korea. APAC clients are particularly attracted by Agilex' FDA-inspected status, and the more than 40% rebate on clinical trial spend that applies in Australia.
Agilex Biolabs specializes in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments, and the only FDA-inspected lab of its type in the region, is located in Adelaide, South Australia in a science and biotech specialist hub.
Dr Popper was first appointed to the Agilex Biolabs Board in July 2019.
Agilex Biolabs CEO Jason Valentine said:
"We are extremely pleased Dr Popper accepted the Board Chair role and we look forward to an exciting phase of growth under her guidance."
"Dr Caroline Popper is a medical doctor, pathologist, health economist, medical consultant and experienced company director, with over 20 years of hands on experience in the healthcare, medical devices and drug discovery fields.
She has managed a wide range of diagnostics, device and drug discovery businesses in both Fortune 500 and start-up settings, at amongst others, Becton Dickinson, bioMerieux, and MDS."
Dr Popper said:
"My clinical experience enables me to help interpret relevant market forces, develop strategies and create partnerships that thrive in the global and fast changing and challenging health care landscape."
"Agilex Biolabs is a stand-out leader in the pharma services space and I look forward to taking on this significant role and being part of the next phase of growth for the company, leveraging its position in the important APAC region."
"The Aglilex Biolabs team of scientists and specialist PhDs is quite exceptional making it well positioned to rapidly deliver bioanalytics for biopharma clients running clinical trials in Australia, Asia and the US, and the EU."
The company specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gurolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).
Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
- Immunophenotyping
- Receptor occupancy
- Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
- PBMC assays and cellular mechanism of action assays (eg: ADCC)
CEO Jason Valentine said:
"Our FDA-inspected facilities have more than 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year we will analyse more than 60,000 samples for pharma/biotechs from US, Europe and APAC."
"By combining specialised expertise, technological innovation and a 20-year track record, we have supported hundreds of preclinical and clinical trials around the world."
"Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition."
Learn more about Agilex Biolabs in this Video: https://youtu.be/3lyodiqqM_k
About Agilex Biolabs
Agilex Biolabs began as a group of academic scientists providing clinical trial and bioanalytical services to the local Australian pharmaceutical industry in the 1980's, and has now grown into a global business for early phase clinical trials. In our 20 years of performing regulated bioanalysis of small and large molecules, we have accelerated hundreds of preclinical and clinical trials around the world. Today, our clients include many of the leading pharmaceutical and biotechnology companies in Asia, Europe and the USA. Call +61 8 83028777 or +1 800 247 1909 or visit https://www.agilexbiolabs.com/.
Agilex Biolabs is built upon four core values that drive our performance:
- Scientific excellence and technological innovation
- Customer focus
- Data integrity and quality assurance
- Timeliness/speed
See us featured in Endpoints https://tinyurl.com/uqmkzcu
Media Contact:
Team@DMGPR.Com
David James
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Topic: Clinical Trial Results
Source: Agilex Biolabs
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Agilex Biolabs |
| May 12, 2022 15:00 HKT/SGT |
|
Elevating Australia's Scientific Acumen: Large Molecule Facility Doubles Size of Australia's Top Bioanalytical Laboratory |
| Oct 19, 2021 15:00 HKT/SGT |
|
Agilex Biolabs Shares How to Select the Right Bioanalytical Tools for Immuno-oncology and Vaccines Studies - OCT Webinar |
| Sept 24, 2021 09:00 HKT/SGT |
|
Agilex Biolabs Announced as Citeline Award Finalist for COVID-19 Vaccine Toxicology Preclinical Research |
| Aug 26, 2021 13:00 HKT/SGT |
|
Agilex Biolabs Partners with Endpoints News for the First Webinar on Rapid Vaccine Development in Australia |
| July 14, 2021 17:00 HKT/SGT |
|
Premier of South Australia Launches $1.5m Vaccine and Immunobiology State-of-the art Laboratory for APAC Clinical Trials |
| May 31, 2021 13:00 HKT/SGT |
|
Agilex Biolabs and Gyros Protein Technologies Partner for BioAnalysis Zone Webinar on Singlicate Analysis |
| May 21, 2021 11:00 HKT/SGT |
|
Agilex Biolabs Partners with Endpoints News on Deconvoluting Inflammation and Immunology for Clinical Trials |
| May 17, 2021 21:00 HKT/SGT |
|
Agilex Biolabs' Toxicology Tapped for SARS-CoV-2 Vaccine Research |
| Apr 30, 2021 13:00 HKT/SGT |
|
Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results |
| Apr 29, 2021 04:00 HKT/SGT |
|
Agilex Biolabs and B2S Life Sciences on Immunoassay Bioanalysis for Clinical Trials |
| More news >> |
 |
|
|
|
